Fig. 4: Targeting CD38 in vivo improves metabolic fitness and cognition in 5xFAD mice.
a IgG or anti-CD38 administration regime. b Tensor component analysis (TCA) based on metabolic and physical parameters (5xFAD - IgG, n = 7; 5xFAD - αCD38, n = 8). TCA distance, computed after TCAM analysis, relative to wild-type (WT) - Vehicle mice (n = 4). Bounds of the box extend from the 25th to 75th percentiles, with an internal line plotted at the median, and whiskers defined by the minimum and maximum values. c Novel object recognition (NOR) cognitive performance of 5xFAD - IgG (n = 16) and 5xFAD - αCD38-treated mice (n = 17), 1 month after initiation of the treatment. WT - Vehicle mice (n = 7) are shown as technical controls. Results are pooled from four independent experiments. d Glucose level in hippocampi of 10 to 12-month-old 5xFAD - IgG (n = 15) and 5xFAD - αCD38-treated mice (n = 12). Results are pooled from five independent experiments. e IL-1β quantification in cortices of 10 to 12-month-old 5xFAD - IgG (n = 15) and 5xFAD - αCD38-treated mice (n = 13), across four independent experiments (average of mice/group/experiment is plotted) as assessed by ELISA. WT - Vehicle mice (n = 16) were used as technical controls. P values are based on one-way ANOVA with Dunnett’s multiple comparisons tests (b), one-way ANOVA with Bonferroni’s multiple comparisons tests (c), two-tailed Mann–Whitney U tests (d), and one-way RM ANOVA with Bonferroni’s multiple comparisons test (e). All data show the mean ± SEM. *P < 0.05, **P < 0.01. Exact P values are indicated in Supplementary Data 1. Source data are provided as a Source Data file.
